Tsuyoshi Shirakawa

Tsuyoshi Shirakawa

Auto-generated profile, based on publicly available information

Tsuyoshi Shirakawa

Clinical Hematology Oncology Treatment Study Group, 1-14-6 Muromi-gaoka, Nishi-ku, Fukuoka-shi, Fukuoka 819-0030, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2014 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
TSTsuyoshi Shirakawa
Tsuyoshi Shirakawa
KKKen Kato
Ken Kato
KNKengo Nagashima
Kengo Nagashima
ANAkiko Nishikawa
Akiko Nishikawa
RSRyoichi Sawada
Ryoichi Sawada
YSYasuhiro Shimada
Yasuhiro Shimada

23 January 2021 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
TOTaiga Otsuka
Taiga Otsuka
TSTsuyoshi Shirakawa
Tsuyoshi Shirakawa
MSMototsugu Shimokawa
Mototsugu Shimokawa
FKFuta Koga
Futa Koga
YKYasunori Kawaguchi
Yasunori Kawaguchi
NUNorio Ureshino
Norio Ureshino

3 January 2022 in BMC Cancer
Verified
Journal Article
Open access
PDF file
TSTaro Shibuki
Taro Shibuki
TMToshihiko Mizuta
Toshihiko Mizuta
MSMototsugu Shimokawa
Mototsugu Shimokawa
FKFuta Koga
Futa Koga
YUYujiro Ueda
Yujiro Ueda
TOTaiga Otsuka
Taiga Otsuka
Background: No reliable nomogram has been developed until date for predicting the survival in patients with unresectable pancreatic cancer undergoing treatment with gemcitabine plus nab–paclitaxel (GnP) or FOLFIRINOX. Methods: This analysis was conducted using clinical data of Japanese patients with unresectable pancreatic cancer undergoing GnP or FOLFIRINOX treatment obtained from a multicenter study (NAPOLEON study). A Cox proportional hazards model was used to identify the independent prognostic factors. A nomogram to predict 6–, 12–, and 18–month survival probabilities was generated, validated by using the concordance index (C–index), and calibrated by the bootstrapping method. And then, we attempted risk stratification for survival by classifying the patients according to the sum of the scores on the nomogram (total nomogram points). Results: A total of 318 patients were enrolled. A prognostic nomogram was generated using data on the Eastern Cooperative Oncology Group performance status, liver metastasis, serum LDH, serum CRP, and serum CA19–9. The C–indexes of the nomogram were 0.77, 0.72 and 0.70 for 6–, 12–, and 18–month survival, respectively. The calibration plot showed optimal agreement at all points. Risk stratification based on tertiles of the total nomogram points yielded clear separations of the survival curves. The median survival times in the low–, moderate–, and high–risk groups were 15.8, 12.8 and 7.8 months (P<0.05), respectively. Conclusions: Our nomogram might be a convenient and inexpensive tool to accurately predict survival in Japanese patients with unresectable pancreatic cancer undergoing treatment with GnP or FOLFIRINOX, and will help clinicians in selecting appropriate therapeutic strategies for individualized management.

30 May 2024 in Scientific Reports
Verified
Journal Article
Open access
PDF file
TKTomoko Kodama
Tomoko Kodama
TITakashi Imajima
Takashi Imajima
MSMototsugu Shimokawa
Mototsugu Shimokawa
TOTaiga Otsuka
Taiga Otsuka
MKMasahiro Kawahira
Masahiro Kawahira
KMKenji Mitsugi
Kenji Mitsugi
Nanoliposomal irinotecan with fluorouracil and folinic acid (NFF) is a standard regimen after gemcitabine-based therapy for patients with unresectable or recurrent pancreatic cancer. However, there are limited clinical data on its efficacy and safety in the real-world. We therefore initiated a retrospective and prospective observational study (NAPOLEON-2). The results of the retrospective part were reported herein. In this retrospective study, we evaluated 161 consecutive patients who received NFF as second-or-later-line regimen. The main endpoint was overall survival (OS), and the other endpoints were response rate, disease control rate, progression-free survival (PFS), dose intensity, and adverse events (AEs). The median age was 67 years (range, 38–85 years). The median OS and PFS were 8.1 and 3.4 months, respectively. The objective response and disease control rates were 5% and 52%, respectively. The median relative dose intensity was 81.6% for nanoliposomal irinotecan and 82.9% for fluorouracil. Grade 3 or 4 hematological and nonhematological AEs occurred in 47 and 42 patients, respectively. Common grade 3 or 4 AEs included neutropenia (24%), anorexia (12%), and leukocytopenia (12%). Subanalysis of patients treated with second-line and third-or-later-line demonstrated no statistical significant difference in OS (7.6 months vs. 9.1 months, respectively; hazard ratio, 0.92; 95% confidence interval, 0.64–1.35; p = 0.68). In conclusion, NFF has acceptable efficacy and safety profile even in real-world clinical settings. The prospective study is in progress to validate these findings.

3 August 2021 in Pancreas
Verified
Journal Article
Closed access
SAShiho Arima
Shiho Arima
MKMachiko Kawahira
Machiko Kawahira
MSMototsugu Shimokawa
Mototsugu Shimokawa
AIAkio Ido
Akio Ido
FKFuta Koga
Futa Koga
TOTaiga Otsuka
Taiga Otsuka
Objectives: FOLFIRINOX (FFX, a combination of oxaliplatin, irinotecan, fluorouracil, and leucovorin) and gemcitabine plus nab-paclitaxel (GnP) have been used as standard, first-line treatments for advanced pancreatic cancer. However, no study has compared the efficacy of the 2 regimens. This study retrospectively compared the efficacy and safety of the 2 regimens in patients with locally advanced pancreatic cancer. Methods: We reviewed the records of patients with locally advanced pancreatic cancer who started FFX or GnP as first-line chemotherapy as part of a multicenter retrospective study in patients with unresectable pancreatic cancer treated with FFX or GnP (NAPOLEON study). Results: Sixteen of the 63 patients were treated with FFX, and the other 47 patients were treated with GnP between December 2013 and March 2017. There were no significant differences in median overall survival rate between the GnP (15.5 months) and FFX (14.3 months, P = 0.60) groups or median progression-free survival rate between the GnP (8.8 months) and FFX (8.1 months, P = 0.51) groups. Both treatments were generally well tolerated, although anorexia was more severe in the FFX group than in the GnP group. Conclusions: The effects of FFX and GnP were similar but resulted in different toxicities, which could guide agent choice.

20 May 2023 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
AKAzusa Komori
Azusa Komori
SOSatoshi Otsu
Satoshi Otsu
MSMototsugu Shimokawa
Mototsugu Shimokawa
TOTaiga Otsuka
Taiga Otsuka
FKFuta Koga
Futa Koga
KMKenji Mitsugi
Kenji Mitsugi